Moderna Developing Single-Dose Booster for COVID-19, Flu
Moderna is working on a new booster vaccine, mRNA-1073, that combines the drugmaker’s COVID-19 shot with its experimental flu vaccine in a single dose.
The combination vaccine is meant to target both the SARS-CoV-2 spike protein that the coronaviruses uses to enter human cells and the influenza hemagglutinin glycoprotein that plays a key role in influenza infections.
Moderna said that “robust antibody responses” have been observed in a mid-stage study assessing a booster dose of its existing COVID-19 vaccine, mRNA-1273. And the company has also fully enrolled a phase 1 study evaluating its next-generation COVID-19 vaccine, mRNA-1283.
In other Moderna news, the drugmaker announced a manufacturing deal with National Resilience, which will produce drug substance for Moderna’s COVID-19 vaccine at its Mississauga, Ontario plant. Moderna projected in April that it expects to produce 800 million to 1 billion COVID-19 vaccine doses this year, building to 3 billion doses in 2022. ― Jason Scott